

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season**

as of December 27, 2019

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	9 <sup>a</sup> (2.3%)	21 <sup>b</sup> (0.9%)	21 <sup>b</sup> (0.9%)	0	0	204 (100%)	34 <sup>c</sup> (8.0%)	0	0	0	0	157 (100%)	0	0	1 <sup>d</sup> (0.5%)	0	0
<b>Number of viruses tested</b>	395	2,252	2,252	373	373	204	424	357	357	357	357	157	44	193	193	193	193
<b>Number of viruses reported</b>	3,076						4,730						652				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 3

<sup>b</sup> Patients without treatment 4

<sup>c</sup> Patients without treatment 5

<sup>d</sup> Patients without treatment 1